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Abstract The (CA)n microsatellite repeat marker D7S522 is
located on human chromosome 7q31.1 and is frequently deleted
in a variety of human cancers, including squamous cell
carcinomas of the head and neck, prostate cancers, renal cell
carcinomas, ovarian adenocarcinomas, colon carcinomas, and
breast cancers. In addition, D7S522 spans FRA7G, a known
common fragile site on human chromosome 7. Based on these
studies, it has been proposed that an as yet unidentified tumor
suppressor gene (or genes) is contained within or located in close
proximity to this locus. However, the identity of the candidate
tumor suppressor gene at the D7S522 locus remains unknown.
Here, we show that the human genes encoding caveolins 1 and 2
are contained within the same human genomic BAC clones and
co-localize to the q31.1-q31.2 region of human chromosome 7, as
seen by FISH analysis. In addition, we determined the intron-
exon boundaries of the human caveolin-1 and -2 genes. The
human caveolin-1 gene contains three exons, while the human
caveolin-2 gene contains two exons. Interestingly, the boundary
of the last exon of the human caveolin-1 and caveolin-2 genes are
analogous, suggesting that they arose through gene duplication at
this locus. (CA)n microsatellite repeat marker analysis of these
caveolin genomic clones indicates they contain the marker
D7S522 (located at 7q31.1), but not other microsatellite repeat
markers tested. The close proximity of caveolins 1 and 2 to the
D7S522 locus was independently confirmed by using a panel of
MIT/Whitehead human STS markers that are known to map in
the neighborhood of the D7S522 locus. As it has been previously
shown that caveolin 1 possesses transformation suppressor
activity (Koleske, A.J., Baltimore, D. and M.P. Lisanti (1995)
Proc. Natl. Acad. Sci. USA 92, 1381^1385; Engelman, J.A. et
al. (1997) J. Biol. Chem. 272, 16374^16381), we propose that the
caveolin-1 gene may represent the candidate tumor suppressor
gene at the D7S522 locus on human chromosome 7q31.1.
z 1998 Federation of European Biochemical Societies.
1. Introduction
Deletion of the q31 region of human chromosome 7 has
been implicated in the pathogenesis of many di¡erent types
of human cancers, such as oral squamous cell carcinomas [1^
3], prostate carcinomas [4^7], adenocarcinoma of the stomach
[8], renal cell carcinomas [9], ovarian carcinomas [10,11], col-
orectal carcinomas [3], mammary carcinomas [7,12^14], pan-
creatic carcinomas [15], and uterine leiomyomas and sarcomas
[16,17]. Detection of such deletions has been performed in
most cases using LOH (loss of heterozygosity) analysis, by
employing speci¢c (CA)n repeat microsatellite polymorphic
markers that map to the 7q31 region. These include, but are
not limited to, the following GeŁneŁthon markers: D7S471;
D7S480; D7S486; D7S490; D7S522; D7S523; D7S649; and
D7S2456. Based on these studies, it has been proposed that an
as yet unknown tumor suppressor gene resides at 7q31.1.
Among these markers, the D7S522 locus appears to be the
most informative. Deletions in the 7q31.1 region are normally
distributed around the D7S522 locus, de¢ning a smallest com-
mon deleted region of V1000 kb [3,4,10,18]. It has been re-
ported that the D7S522 locus is the most commonly deleted
region in primary breast cancers [13]. In addition, loss of
D7S522 was strongly associated with systemic progression
and death due to prostate cancers [4,6]. Loss of the D7S522
locus (7q31.1) also occurs in human squamous cell carcinomas
[1^3], renal cell carcinomas [9], ovarian carcinomas [19], and
colon carcinomas [3]. These published results are summarized
in Table 1. D7S522 also spans the aphidicolin-induced fragile
site FRA7G at 7q31 [9,20]. Given the usefulness of 7q31.1 and
DS7522 LOH as markers for carcinogensis, many laboratories
are currently searching this chromosomal region to identify a
novel tumor suppressor gene that is predicted to reside at this
locus. However, no genes have been previously localized to
the D7S522 locus.
Here, we present conclusive evidence that the genes encod-
ing caveolins 1 and 2 are co-localized at the D7S522 locus. As
it has been reported that caveolin 1 can function as a suppres-
sor of cell transformation in murine ¢broblasts and human
breast cancer cell lines [21^25], we suggest that caveolin 1 may
represent the missing tumor suppressor at the D7S522
(7q31.1) locus.
2. Materials and methods
2.1. Isolation of human genomic BAC clones
Probes corresponding to the full-length cDNAs of human caveolin
1 and caveolin 2 were used to screen a human genomic BAC library
(Release II; Genome Systems). Intron-exon boundaries of the human
caveolin-1 and caveolin-2 genes were established using a combination
of direct dideoxy sequencing of the human BAC clones and PCR
analysis with primers based on the known intron-exon organization
of the murine caveolin-1 and caveolin-2 genes. The presence of the
coding exons of human caveolins 1 and 2 within a given BAC clone
was also veri¢ed by PCR analysis.
2.2. Fluorescence in situ hybridization (FISH) analysis
Chromosomal localization of the human caveolin-1 and caveolin-2
genes was carried out in collaboration with Genome Systems. Brie£y,
a given human genomic BAC clone was labeled with digoxigenin
dUTP by nick translation. The labeled probe was combined with
sheared human DNA and hybridized to normal metaphase chromo-
somes (derived from PHA-stimulated human peripheral blood lym-
phocytes). Hybridization was carried out in a solution containing 50%
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formamide, 10% dextran sulfate and 2USSC. Hybridization signals
were detected by incubating the hybridized slides with FITC-labeled
anti-digoxigenin IgGs. Chromosomes were also counter-stained with
DAPI. In double-labeling experiments, a biotin-labeled probe speci¢c
for the centromeric region of human chromosome 7 was used to
con¢rm the localization of the caveolin-1 and caveolin-2 genes. The
biotin-labeled probe was detected with Texas-Red conjugated avidin.
For each caveolin genomic clone examined, a total of 80 metaphase
cells were analyzed with s 70% showing speci¢c labeling.
2.3. Microsatellite and STS marker analysis
Isolated human genomic BAC clones containing caveolin genes
were subjected to microsatellite marker analysis by PCR with the
following 19 GeŁneŁthon markers: D7S23; D7S471; D7S480;
D7S486; D7S490; D7S522; D7S523; D7S525; D7S633; D7S649;
D7S650; D7S655; D7S677; D7S685; D7S687; D7S1482; D7S1809;
D7S2456; and D7S2847. The following nine MIT/Whitehead STS
markers were also evaluated: WI-455; WI-1841; WI-3876; WI-
4433; WI-5336; WI-7597; WI-7882; WI-8693; and WI-8726.
GeŁneŁthon and MIT/Whitehead primer pairs were obtained from Re-
search Genetics.
3. Results
3.1. Isolation of human genomic clones encoding caveolin 1 and
caveolin 2
The human cDNAs encoding caveolins 1 and 2 were used
to screen a human genomic BAC library to obtain corre-
sponding clones containing the human genes encoding caveo-
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Table 1
Reported loss of the D7S522 locus in human cancers
Tumor type D7S522 LOH References
Squamous cell V16%; V53% [1,3]
Colon V80% [3]
Prostate V83% [4]
Renal cell V24% [9]
Ovarian V73%, V34% [10,19]
Mammary V83% [13]
Table 2
Human genomic BAC clones containing caveolin 1 and caveolin 2
Clone# Insert size Genes FISH analysis
1 V80^120 kb Cav-1 and Cav-2 7q31.1-31.2
2 V80^120 kb Cav-1 and Cav-2 N.D.
3 V80^120 kb Cav-1 and Cav-2 7q31.1-31.2
4 V80^120 kb Cav-1 and Cav-2 N.D.
5 V80^120 kb Cav-1 and Cav-2 N.D.
The presence of Cav-1 and Cav-2 genes was initially determined by
colony hybridization analysis using the corresponding human cDNAs
as probes. The presence of Cav-1 and Cav-2 was later con¢rmed by
PCR analysis using primers to their known coding sequence. N.D.,
not determined.
Fig. 1. Chromosomal localization of the genes encoding human caveolin-1 and caveolin-2. The chromosomal localization was determined by
FISH analysis. A: Hybridization using human genomic BAC clone 1. B: Hybridization using human genomic BAC clone 3. In both cases, the
hybridization signal (green) was localized to the long arm of chromosome 7 in an area which corresponds to band 7q31.1-31.2 (according to
the current accepted International System for Human Cytogenetic Nomenclature). The identity of chromosome 7 was con¢rmed by double-la-
beling using a probe that is speci¢c for the centromere of chromosome 7 (red; right panels).
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lins 1 and 2. Through this screening approach a total of
¢ve independent positive clones were isolated and are listed
in Table 2. All ¢ve clones contain both caveolins 1 and 2.
These results indicate that the genes encoding caveolins 1
and 2 must be in relatively close proximity, as the average
insert size of these human BAC clones is estimated to be
V80-120 kb.
3.2. Chromosomal localization of human caveolin-1 and
caveolin-2 genes
These genomic clones were next used as probes to deter-
mine the chromosomal localization of the human caveolin-1
and caveolin-2 genes by £uorescence in situ hybridization
(FISH) analysis (Fig. 1).
Initial trials indicated that hybridization resulted in the
speci¢c labeling of the long arm of a group C chromosome,
with the size, morphology, and banding pattern expected
for human chromosome 7. The identity and exact location
was determined by double-labeling experiments employing
a probe that speci¢cally labels the centromere of chromosome
7.
For the two independent clones examined, both hybridized
speci¢cally at a position that is V55% the distance from the
centromere to the telomere of 7q. This area corresponds pre-
cisely to the region 7q31.1-31.2, according to the International
System for Human Cytogenetic Nomenclature. Greater than
70% of 80 metaphase cells analyzed showed speci¢c labeling.
Searches of the NCBI Gene Map of the Human Genome
indicate that other genes in the neighborhood of the 7q31-32
region include: CFTR (cystic ¢brosis transmembrane conduc-
tance regulator); interferon-related protein PC4; glia-derived
nexin; endothelin receptor type B-like protein; Wnt-2;
PPP1R3 (protein phosphatase 1, glycogen binding regulatory
subunit) ; the MET proto-oncogene; laminin (beta-1); ¢lamin-
2 (actin-binding protein-280); carboxypeptidase A1; and lep-
tin (OB locus in mice).
We have previously localized the human caveolin-3 gene to
chromosome 3p25 [26,27]. Interestingly, mutations within the
coding region of the human caveolin-3 gene cause autosomal
dominant and recessive forms of limb-girdle muscular dystro-
phy [26,27].
3.3. Genomic organization of human caveolin 1 and caveolin 2
Fig. 2A,B shows the intron-exon organization of the genes
encoding human caveolins 1 and 2. Intron-exon boundaries
were established using a combination of direct dideoxy se-
quencing of the human BAC clones and PCR analysis with
primers based on the known intron-exon organization of the
murine caveolin-1 and caveolin-2 genes. Note that the human
caveolin-1 gene consists of three exons, while the human cav-
eolin-2 gene contains only two exons. Interestingly, the last
exon of both caveolin-1 and -2 genes shows virtually the same
boundary, suggesting that they arose through gene duplica-
tion at this locus. The presence of the coding exons of cav-
eolins 1 and 2 within a given BAC clone was also veri¢ed by
PCR using the primer pairs listed in Table 3, and an example
is shown in Fig. 2C.
3.4. Caveolins 1 and 2 are co-localized to the D7S522 locus
(7q31.1)
To more precisely determine the location of the human
caveolin-1 and caveolin-2 genes, we next performed microsa-
tellite marker analysis on the corresponding human genomic
BAC clones.
As 7q31.1 corresponds to a region that is frequently deleted
in human cancers, numerous microsatellite markers have been
used for LOH analysis of this region. Through literature
FEBS 20894 8-10-98 Cyaan Magenta Geel Zwart
Fig. 2. Genomic organization of the human caveolin-1 and caveo-
lin-2 genes. Exon boundaries are as indicated. A: Human caveolin-1
gene; B: human caveolin-2 gene. A similar genomic organization
has been reported for the genes encoding murine caveolin 1 and
caveolin 2 [54]. Note that for human caveolin 1 two amino acid res-
idues have been changed to re£ect the correct protein sequence de-
rived from translation of numerous human ESTs. The residue at po-
sition 82 is now D, not H; and the residue at position 144 is now
I, not T. These corrected residues are conserved in all mammalian
caveolin-1’s sequenced to date. C: The presence of the coding exons
of caveolins 1 and 2 within a given BAC clone was veri¢ed by PCR
using the primer pairs listed in Table 3. Human genomic BAC clone
1 served as the template for these reactions.
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searches, we identi¢ed the eight most common markers as
follows: D7S471; D7S480; D7S486; D7S490; D7S522;
D7S523; D7S649; and D7S2456. These markers, correspond-
ing primer sequences, and the expected size of their PCR
products are as indicated in Table 4.
Table 5 shows the results of this analysis. Only microsatel-
lite marker D7S522 was detected and is present in all ¢ve
caveolin genomic clones. In the case of D7S522, a PCR prod-
uct of V220 bases was observed as expected (Fig. 3). Direct
dideoxy sequencing of this PCR product unequivocally con-
¢rmed its identity as microsatellite marker D7S522 (Fig. 3).
A search of The Cooperative Human Linkage Center
(CHLC) Database indicated that D7S522 is located on human
chromosome 7 within interval 14 (which corresponds to the
7q31.1 region). This is in accordance with our mapping results
from FISH analysis. Currently, the only known gene in inter-
val 14 is the MET proto-oncogene (also known as the hepa-
tocyte growth factor receptor or epithelial scatter factor re-
ceptor). However, based on current physical maps of the
region, the MET proto-oncogene is located V500 kb down-
stream of the D7S522 locus [18].
Fig. 4 shows the location of the human caveolin-1 and -2
genes with respect to the markers D7S486, D7S522, and the
MET proto-oncogene. This represents the smallest common
deleted region (V1000 kb), as previously de¢ned by LOH
analysis [4,18]. Note that D7S522 is at the center of this re-
gion. Given that the average insert size of the caveolin con-
taining BAC genomic clones is V80^100 kb, the caveolin-1
and -2 genes must be located a maximum distance of V100
kb upstream or downstream of D7S522. Thus, the caveolin-1
and -2 genes are at the center of this smallest common deleted
region.
In addition, through this search we identi¢ed 11 other mi-
crosatellite markers that are located in interval 14 as follows:
D7S23; D7S525; D7S633; D7S650; D7S655; D7S677;
D7S685; D7S687; D7S1809; D7S1482; and D7S2847. How-
ever, none of these markers were detected by PCR analysis of
the human genomic caveolin BAC clones (not shown).
3.5. What about STS markers located near the D7S522 locus?
We next searched the NCBI database to identify human
STS markers that are located in close proximity to the micro-
satellite marker D7S522. Through this search, we identi¢ed
nine MIT/Whitehead STS markers that map in the neighbor-
hood of the D7S522 locus: WI-455; WI-1841; WI-3876; WI-
4433; WI-5336; WI-7597; WI-7882; WI-8693; and WI-8726.
These STS markers, corresponding primer sequences, and the
expected size of their PCR products are described in Table 6.
Interestingly, only the STS marker WI-5336 was detected
and is present in all ¢ve caveolin genomic clones. In the case
of WI-5336, a PCR product of V110 bases was observed as
expected (Fig. 5). This is in accordance with current MIT/
Whitehead Genome Center maps showing that WI-5336 and
WI-455 STS markers are located closest to the microsatellite
marker D7S522 in the following order: D7S486; WI-5336;
D7S522; and WI-455. Thus, the use of these STS markers
independently con¢rms the close proximity of the human cav-
eolin-1 and caveolin-2 genes to the D7S522 locus.
3.6. The caveolin-1 gene is located in extremely close proximity
to D7S522
In order to determine the position of the caveolin-1 and
caveolin-2 genes with respect to the D7S522 locus, we per-
formed a series of PCR reactions using primers to the coding
sequences of the caveolin genes and primers to D7S522. Hu-
man genomic BAC clone 1 served as the template for these
reactions. This clone contains both Cav-1 and Cav-2 genes
(Fig. 2C; Table 7) and the marker D7S522 (Fig. 3).
PCR with primers to the 5P end of Cav-1/exon 1 and the 3P
end of D7S522 yielded a strong product of V7^10 kb in
length; similar results were also obtained by PCR with prim-
ers to the 5P end of Cav-1/exon 2 and the 3P end of D7S522.
Both of these PCR products were gel-puri¢ed and next sub-
jected to further PCR-based mapping studies using primer
pairs to detect Cav-1/exon 2, Cav-1/exon 3, Cav-2/exon 1,
Cav-2/exon 2, and D7S522.
Fig. 6A shows that both of these V7^10-kb fragments con-
tain Cav-1/exon 2, Cav-2/exon 1, Cav-2/exon 2, and D7S522,
but lack Cav-1/exon 3. Based on these studies, a ¢rst approx-
imation map of this region was constructed and is presented
in Fig. 6B. Interestingly, these results suggest that both the
Cav-2 gene and D7S522 are present within the second intron
of the Cav-1 gene. In support of this map, we also observed
that 3 of the 5 human genomic BAC clones that we isolated
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Table 4
Commonly used 7q microsatellite markers, primer sequences, and the expected size of their PCR products
Marker Forward primer (5P^3P) Reverse primer (5P^3P) Expected size (base pairs)
D7S471 AGCAGCTATTATGGAATTGC CAACATATGCAAGGTGCCTA 181^193
D7S480 CTTGGGGACTGAACCATCTT AGCTACCATAGGGCTGGAGG 189^206
D7S486 AAAGGCCAATGGTATATCCC GCCCAGGTGATTGATAGTGC 114^146
D7S490 CCTTGGGCCAATAAGGTAAG AGCTACTTGCAGTGTAACAGCATTT 92^106
D7S522 GCCAAACTGCCACTTCTC ACGTGTTATGCCACTCCC 217^229
D7S523 CTGATTCATAGCAGCACTTG AAAACATTTCCATTACCACTG 224^240
D7S649 ATTTTGATCCCCAGCA GCTTTATTATGTCTGTTGTATGA 275^281
D7S2456 CTGGAAATTGACCTGAAACCTT ACAGGGGTCTCTCACACATATTA 238^252
Table 3
Primer pairs used to amplify the coding regions of the human caveolin-1 and -2 genes and the expected size of their PCR products
Caveolin region Forward primer (5P^3P) Reverse primer (5P^3P) Expected size (base pairs)
hCav-1 exon 2 GGACATCTCTACACCGTTCCC CTTGACCACGTCATCGTTGAG 165
hCav-1 exon 3 ATTGACTTTGAAGATGTGATT TTATATTTCTTTCTGCAAGTT 342
hCav-2 exon 1 ATGGGGCTGGAGACGGAGAAG CTTGAGATGCGAGTTGAGCCG 150
hCav-2 exon 2 CTGGGCTTCGAGGATGTGATC TCAATCCTGGCTCAGTTGCAG 339
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contain Cav-1/exon 2, Cav-2/exon 1, Cav-2/exon 2, and
D7S522, but lack Cav-1/exon 3 (Table 7).
We are currently sequencing the entire genomic BAC clone
1 (V80^100 kb) and its derivatives to obtain a more detailed
map of the region.
4. Discussion
Caveolae are 50^100 nm vesicular invaginations of the plas-
ma membrane [28,29]. It has been proposed that caveolae
participate in vesicular tra⁄cking events and signal transduc-
tion processes. Caveolin, a 21^24-kDa integral membrane pro-
tein, is a principal component of caveolae membranes in vivo
[30^34].
Caveolin is only the ¢rst member of a new gene family; as a
consequence, caveolin has been re-termed caveolin-1 [35].
Caveolin-2 shows the same tissue distribution as caveolin-1,
co-localizes with caveolin-1, and forms a hetero-oligomeric
complex with caveolin-1 in vivo [36]. In contrast, the expres-
sion of caveolin-3 is muscle-speci¢c [37^39]. It has been pro-
posed that caveolin family members function as sca¡olding
proteins [40] to organize and concentrate speci¢c lipids (chol-
esterol and glyco-sphingolipids; [41^43]) and lipid-modi¢ed
signaling molecules (Src-like kinases, H-Ras, eNOS and G-
proteins; [41,44^48]) within caveolae membranes.
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Fig. 3. Caveolins 1 and 2 are located at the D7S522 locus (7q31.1). Primers corresponding to eight GeŁneŁthon microsatellite markers from the
7q31 region were used to perform PCR analysis with the human genomic caveolin BAC clones as the template. A: In the case of D7S522, a
PCR product of V220 bases was observed as expected. B: Direct dideoxy sequencing of this PCR product unequivocally con¢rmed its identity
as the microsatellite marker D7S522. The regions contained within the PCR primers are boxed. Note that sequence of the observed PCR prod-
uct and the polymorphic marker D7S522 are 97% identical at the nucleotide level. Using the D7S522 primers, identical results were obtained
by direct dideoxy sequencing of the human caveolin genomic BAC clones.
Fig. 4. Location of the human caveolin-1 and -2 genes with respect
to the markers D7S486, D7S522, and the MET proto-oncogene.
The smallest common deleted region (V1000 kb), as previously de-
¢ned by LOH analysis, is shown [4,18]. Note that D7S522 is located
at the center of this region. More speci¢cally, D7S522 is V500 kb
downstream from the marker D7S486 and V500 kb upstream from
the MET proto-oncogene. Given that the average insert size of the
caveolin containing BAC genomic clones is V80^100 kb, the caveo-
lin-1 and -2 genes must be located a maximum distance of V100
kb upstream or downstream of D7S522. Thus, the position of the
caveolin-1 and -2 genes lies at the center of this smallest common
deleted region.
Table 5
Microsatellite marker analysis of human caveolin genomic BAC
clones
Marker Clone #
1 2 3 4 5
D7S471 3 3 3 3 3
D7S480 3 3 3 3 3
D7S486 3 3 3 3 3
D7S490 3 3 3 3 3
D7S522 + + + + +
D7S523 3 3 3 3 3
D7S649 3 3 3 3 3
D7S2456 3 3 3 3 3
Microsatellite repeat marker analysis was performed by PCR using
the corresponding GeŁneŁthon primer pairs. + indicates that a PCR
product of the expected size was observed.
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Caveolin-1 binding can functionally suppress the GTPase
activity of hetero-trimeric G-proteins and inhibit the kinase
activity of Src-family tyrosine kinases, EGF-receptor kinases,
protein kinase C isoforms, and components of the p42/44
MAP kinase cascade (MEK and ERK) through a common
caveolin domain, termed the caveolin-sca¡olding domain
[24,44^46,49^52]. In all cases examined, the caveolin binding
motif is located within the enzymatically active catalytic do-
main of a given signaling molecule. For example, in the case
of tyrosine and serine/threonine kinases, a kinase domain con-
sists of 11 conserved subdomains (I^XI) [24,50,51]. The cav-
eolin binding motif is located within conserved kinase subdo-
main number IX, suggesting that caveolin could function as a
general kinase inhibitor [53]. This hypothesis has been substan-
tiated by the observation that the caveolin sca¡olding domain
inhibits Src family tyrosine kinases (c-Src/Fyn), EGF-R, Neu,
PKC, MEK and ERK with similar potencies [24,46,50^52].
Thus, we have suggested that caveolin may function as a
negative regulator of many di¡erent classes of signaling mol-
ecules through the recognition of speci¢c caveolin-binding
motifs [49,53].
Here, we show that the genes encoding human caveolins 1
and 2 co-localize to the q31.1 region of human chromosome 7
by FISH analysis. In a previous report, we showed that the
murine genes encoding caveolins 1 and 2 are co-localized to
the A2 region of mouse chromosome 6 [54]. A search of the
NCBI Human/Mouse Homology Map reveals that the human
chromosomal region 7q31 corresponds precisely to the murine
chromosomal region 6-A2. In accordance with these FISH
mapping studies, we demonstrate that these human caveolin-
1 and -2 genomic clones contain the (CA)n microsatellite re-
peat marker D7S522 and the STS marker WI-5336 that have
been independently localized to the 7q31.1 region.
How does the chromosomal localization of caveolin-1 cor-
relate with its known transformation suppressor activity? In-
terestingly, D7S522 spans a known common fragile site on
human chromosome 7 (FRA7G) and D7S522 is frequently
deleted in a variety of human cancers, including squamous
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Table 6
MIT/Whitehead human STS markers in the region of D7S522, primer sequences, and the expected size of their PCR products
Marker Forward primer (5P^3P) Reverse primer (5P^3P) Expected size (base pairs)
WI-455 CCTCTGATCATCTTCTGATCC GTAAAATGGATAGATTCGGACC 250
WI-1841 CTACGTAGAAGAGAAAGGAAACGG TTGGAGGTCTGAGTCGGAGT 208
WI-3876 GATTTCCCTAGAGCCTGGCT GAGAGAGACCTTTCAAAATGTTCC 203
WI-4433 TGATATTAAAATGGACAAGAAATGG GTCTTCATCATTCTCAAAACTCCA 100
WI-5336 ATAAGACCAGATCAAGGACAGACC AACAATACACAAGCCCCTGC 112
WI-7597 CAAGTGGTTTTACAGCTACCACC CACCCAATAGTTACAGAATATTGCC 328
WI-7882 GATGCTACAGGAATTTCAAGCC TTATATTCTCAATGCTTTCAAAGCC 324
WI-8693 AAAACTGTGTTGGAATAAGAAAACG AGTACCATACCTTACAGAGCTGGG 106
WI-8726 TATATCCATGGACAGGCTTGG GAGACCATGATTTATATTGGATTGC 124
Fig. 5. STS marker analysis of the human caveolin genomic BAC
clones. Primers corresponding to nine MIT/Whitehead STS markers
located in the neighborhood of the D7S522 locus were used to per-
form PCR analysis with the human genomic caveolin BAC clones
as the template. In the case of WI-5336, a PCR product of V110
bases was observed as expected. Lanes 1 and 11 are controls using
primers for ampli¢cation of D7S522 (V220 bases). Human genomic
BAC clone 1 served as the template for these reactions.
Fig. 6. Location of the human caveolin-1 gene with respect to the
D7S522 locus. A: PCR with primers to the 5P end of Cav-1/exon 1
and the 3P end of D7S522 yielded a strong product of V7^10 kb in
length; similar results were also obtained by PCR with primers to
the 5P end of Cav-1/exon 2 and the 3P end of D7S522 (not shown).
Human genomic BAC clone 1 served as the template for these reac-
tions. Both of these V7^10-kb PCR products were gel-puri¢ed and
next subjected to further PCR-based mapping studies using primer
pairs to detect Cav-1/exon 2, Cav-1/exon 3, Cav-2/exon 1, Cav-2/
exon 2, and D7S522. The expected sizes of these PCR products are
listed in Tables 3 and 4. Panel A shows that both of these V7^10-
kb fragments contain Cav-1/exon 2, Cav-2/exon 1, Cav-2/exon 2,
and D7S522, but lack Cav-1/exon 3. A representative gel is shown
using one of the V7^10-kb fragments as the template (lanes 1^5) or
human genomic BAC clone 1 (lane 6). B: Based on the PCR analy-
sis described in panel A, a ¢rst approximation map of this genomic
region was constructed.
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cell carcinomas, prostate cancers, renal cell carcinomas, ovar-
ian adenocarcinomas, colon carcinomas, and breast cancers
(see Section 1). Based on these studies, it has been proposed
that an as yet unidenti¢ed tumor suppressor gene (or genes) is
contained in close proximity to the D7S522 locus.
The unidenti¢ed tumor suppressor gene located at D7S522
(7q31.1) may be caveolin 1 given that: (i) the caveolin-1 gene
is localized to this chromosomal region; (ii) caveolin-1 mRNA
and protein are down-regulated during cell transformation of
cultured NIH 3T3 cells, in transgenic mouse models of breast
cancer, and in cell lines derived from human breast cancers
[21^25]; and (iii) recombinant expression of caveolin-1 in
transformed NIH 3T3 cells or cell lines derived from human
breast cancers can suppress their transformed phenotype such
as anchorage-independent growth in soft agar [23,25]. As
many normal adult tissues express caveolin 1, it will be im-
portant to determine whether any chromosomal deletions or
rearrangements of the D7S522 locus lead to a loss of caveolin-
1 mRNA or protein expression during tumor formation or
metastasis.
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Table 7
Summary of the PCR analysis of ¢ve independent human genomic caveolin BAC clones
Clone # Cav-1 Cav-2 Markers
Exon 2 Exon 3 Exon 1 Exon 2 D7S522 WI-5336
1 + + + + + +
2 + 3 + + + +
3 + + + + + +
4 + 3 + + + +
5 + 3 + + + +
Primer pairs used to amplify the coding regions of human caveolin 1 and 2, and the markers D7S522 and WI-5336, as well as the expected size of
their PCR products are described in Tables 3, 4 and 6. + indicates that a PCR product of the expected size was observed.
J.A. Engelman et al./FEBS Letters 436 (1998) 403^410 409
[45] Song, K.S., Li, S., Okamoto, T., Quilliam, L., Sargiacomo, M.
and Lisanti, M.P. (1996) J. Biol. Chem. 271, 9690^9697.
[46] Li, S., Couet, J. and Lisanti, M.P. (1996) J. Biol. Chem. 271,
29182^29190.
[47] Shaul, P.W., Smart, E.J., Robinson, L.J., German, Z., Yuhanna,
I.S., Ying, Y., Anderson, R.G.W. and Michel, T. (1996) J. Biol.
Chem. 271, 6518^6522.
[48] Garcia-Cardena, G., Oh, P., Liu, J., Schnitzer, J.E. and Sessa,
W.C. (1996) Proc. Natl. Acad. Sci. USA 93, 6448^6453.
[49] Couet, J., Li, S., Okamoto, T., Ikezu, T. and Lisanti, M.P. (1997)
J. Biol. Chem. 272, 6525^6533.
[50] Couet, J., Sargiacomo, M. and Lisanti, M.P. (1997) J. Biol.
Chem. 272, 30429^30438.
[51] Oka, N., Yamamoto, M., Schwencke, C., Kawabe, J., Ebina, T.,
Couet, J., Lisanti, M.P. and Ishikawa, Y. (1997) J. Biol. Chem.
272, 33416^33421.
[52] Engelman, J.A., Chu, C., Lin, A., Jo, H., Ikezu, T., Okamoto, T.,
Kohtz, D.S. and Lisanti, M.P. (1998) FEBS Lett. 428, 205^211.
[53] Okamoto, T., Schlegel, A., Scherer, P.E. and Lisanti, M.P. (1998)
J. Biol. Chem. 273, 5419^5422.
[54] Engelman, J.A., Zhang, X.L., Galbiati, F. and Lisanti, M.P.
(1998) FEBS Lett. 429, 330^336.
FEBS 20894 8-10-98 Cyaan Magenta Geel Zwart
J.A. Engelman et al./FEBS Letters 436 (1998) 403^410410
